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Abstract
Background: Children are increasingly being diagnosed with primary hypertension. The absence of comparative
effectiveness research of antihypertensive medications in children has contributed to considerable differences in
prescribing practices among physicians treating children with primary hypertension. Even if parallel-group trials had
established a best overall choice for most of these children, the best medication for an individual may differ from
the best overall medication.
Methods/design: This project consists of a series of systematically administered n-of-1 trials among older children
to verify the need for ongoing antihypertensive treatment and, if so, to identify the preferred single drug therapy
from among the three major classes of drugs commonly used for primary hypertension (angiotensin-converting
enzyme inhibitors, calcium channel blockers, and diuretics). We will determine whether one of these is the
preferred therapy for the great majority of patients. The “preferred” therapy is the drug which produces normal
ambulatory blood pressure, with the greatest reduction in blood pressure without unacceptable side effects. We
will recruit 50 patients from the Houston Pediatric and Adolescent Hypertension Program clinic. For each patient,
the three drugs will be prescribed in random order and each drug will be taken for 2 weeks. The effectiveness of
each therapy will be measured with 24-h ambulatory blood pressure monitoring, and tolerability will be assessed
using a side effect questionnaire. Participants will rotate through treatment periods, repeating drugs and adjusting
doses until the preferred therapy is identified. In assessing whether one of the medications is most effective for the
majority of subjects, the primary outcome will be the percentage of participants for whom each drug is selected as
the preferred therapy. We hypothesize that no drug will be selected for the great majority of the subjects, a finding
that would support consideration of clinical use of n-of-1 trials. Secondary analyses will explore whether patient
characteristics predict which medication will be selected as a preferred drug.
Discussion: This study will help optimize care of participating patients and provide evidence regarding the usefulness
of n-of-1 trials in identifying appropriate treatment for children with hypertension and potentially other disorders.
Trial registration: Clinicaltrials.gov NCT02412761 (registered 4/8/2015).
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Background
Hypertension is one of the most important modifiable
risk factors for adverse health outcomes: premature
death, renal failure, stroke, and myocardial infarction are
each reduced when blood pressure is controlled [1–8].
Hypertension is increasingly diagnosed in children, and
effective treatment will be particularly important to
reduce the ultimate years of healthy life lost to these
problems.
Unfortunately, only sparse data from clinical trials
inform the use of different antihypertensive agents in
children [9]. As a result, the best first-line therapy for
children has not been defined for national guidelines
[10], and clinical practice is highly variable [11–13]. In a
survey of North American pediatric nephrologists, 47 %
chose angiotensin-converting enzyme (ACE) inhibitors;
37 %, calcium channel blockers, and 15 % diuretics as
initial therapy in children with primary hypertension [14].
Large parallel-group randomized clinical trials (RCTs)
are generally required to determine which therapy is
the preferred initial therapy that on average has the
greatest overall benefit. However, that therapy may be
ineffective or harmful for some patients [15]. Parallel-
group RCTs are often far underpowered to identify
important subgroup differences or treatment interac-
tions needed to distinguish such patients [16]. Add-
itionally, subgroup analyses cannot unravel the complex
interplay between multiple characteristics that are simul-
taneously at work within a given individual to modify the
treatment effect [17].
In some circumstances the best treatment for individ-
ual patients may be identified in n-of-1 trials. Such trials
are systematically administered, single patient RCTs in
which the patient serially receives multiple therapies in a
random order [18]. These trials can include allocation
concealment, blinding, and all other features used to
minimize bias in traditional parallel-group RCTs [19].
Unlike traditional RCTs, n-of-1 trials can facilitate treat-
ment recommendations for each individual patient based
on his or her responses to the different therapies [20].
N-of-1 trials provide a formal and more rigorous assess-
ment than the informal “trial of therapy” often used
clinically in prescribing an antihypertensive agent—an
approach that can be biased due to inaccurate or infre-
quent assessments of blood pressure, failure to assess
more than one medication, absence of predefined cri-
teria for success, and physician reluctance to change
therapy. By involving patients and their families in
verifying the presence of hypertension and identifying
the preferred therapy, n-of-1 trials might reduce unneces-
sary treatment and increase adherence when treatment is
needed [21–23].
Guyatt and colleagues, who pioneered n-of-1 trials,
have described the conditions for which they are most
useful [24]. The condition should be chronic and require
prolonged treatment; the therapies should have a rapid
onset and offset of action; the response to treatment
should be accurately measurable; and the physician
should be willing to consider multiple therapies. Such
trials have been performed in a variety of conditions, in-
cluding chronic obstructive lung disease, osteoarthritis,
neuropathic pain, palliative care, traumatic brain injury,
and attention deficit-hyperactivity disorder [25–30]. The
treatment of primary hypertension in children meets
these criteria and is equally well suited for an n-of-1
trial.
Methods
This is a series of n-of-1 trials to compare the effectiveness
and tolerability of lisinopril, amlodipine, and hydrochloro-
thiazide within each patient. Each of these therapies has
previously been proven to be efficacious in blinded
placebo-controlled RCTs [31–33]. The preferred therapy
for each patient is defined a priori as the medication
which yields normal ambulatory blood pressure (BP), with
the greatest reduction in ambulatory wake mean systolic
BP compared to baseline BP and without the presence of
unacceptable side effects. Each n-of-1 trial consists of a
series of 2-week treatment periods which are repeated
until the preferred therapy is identified (Fig. 1). Once the
trial is complete, the patient resumes usual care in the
Pediatric Hypertension Clinic.
Study objectives and hypothesis
The primary objective is to determine whether there are
individual differences in the response to different drug
classes. We hypothesize that no drug will be selected for
80 % or more of the participants, a finding that might
prompt consideration of n-of-1 trials in clinical practice
before selecting a therapy for long-term administration.
The secondary objective is to explore whether there are
baseline characteristics associated with the choice of the
preferred therapy for each patient.
Study setting, eligibility criteria, and recruitment
This study is located in Houston, Texas, with recruitment
occurring from patients attending the Houston Pediatric
and Adolescent Hypertension Program (HPAHP) clinic at
the University of Texas Health Science Center at Hous-
ton (UTHealth). Patients receiving pharmacologic antihy-
pertensive therapy or recently referred patients who meet
criteria for treatment based on ambulatory blood pressure
monitoring (ABPM) are invited to participate if they are
aged 9–22 years and have primary hypertension. Patients
less than 9 years old are not included because younger pa-
tients have a higher likelihood of secondary hypertension,
and would be less likely to comply with the repeated
ABPMs required for the n-of-1 trial. All patients in this
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clinic undergo evaluation for secondary causes of hyper-
tension based on national guidelines [10]. Only those pa-
tients without a compelling indication to select one
particular medication (such as choosing ACE inhibitors or
angiotensin receptor blockers in patients with diabetes)
are considered eligible for participation. Patients with a
Establish baseline BP
Confirm ongoing need for medication
N-of-1 trial complete
Cycle 1
Cycle 2Repeat remaining choices1
If normal ambulatory BP has been achieved for <2  
cycles and further dose adjustment is possible
Drug A
weeks 1-2
Eliminate drug with unacceptable side effects





Eliminate drug with unacceptable side effects
or smallest change from baseline BP
Drug A
weeks 7-8
If normal ambulatory BP has been achieved for 2 
cycles OR ambulatory hypertension persists despite
maximal dosing of all remaining options2
Drug B
weeks 9-10
Repeat remaining choice 3
Drug A
additional 2 weeks
Legend for Figure 1.
1 If normal ambulatory BP is achieved in Cycle 1, continue same dose. 
If ambulatory hypertension persists in Cycle 1, increase doses 
according to Table 1.
2 If maximal dosing recommendations prevent further dose increase 
of monotherapy, n-of-1 trial considered complete, and combination 
therapy is initiated in Pediatric Hypertension Clinic. 
3 If normal ambulatory BP is now achieved after increased dose in 
previous cycle, continue same dose for an additional cycle.  If 
ambulatory hypertension persists in previous cycle, the doses for next 
cycle are adjusted further according to Table 1.  
Fig. 1 N-of-1 design schema
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specific contraindication for any of the three therapies
are excluded.
The n-of-1 trial is offered to all eligible patients as
an optional program. Patients are informed that par-
ticipation is voluntary, and they can withdraw at any
time. Verbal informed consent is obtained from each
participant.
Blinding and randomization
We have made no attempt to alter the medications to
make them identical and indistinguishable to the patients,
partly because of feasibility, cost, and concern that their
effects in clinical practice might be inadvertently altered.
During the n-of-1 trial, when comparing the effectiveness
and tolerability of each therapy with the family, the phys-
ician is blinded to which drug was tested in each time
period by using a summary sheet of ABPM results and
side effects which refers to treatments as first, second, or
third used. The order of the medications given is random-
ized each time they are compared for a patient using an
online random number generator [34].
Blood pressure definitions
Ambulatory hypertension is defined as the combin-
ation of 1) wake or sleep mean ambulatory systolic blood
pressure (SBP) or diastolic blood pressure (DBP) greater
than the height-sex referenced 95th percentile and 2) BP
load > 25 %, based on standardized values from the
2014 American Heart Association Scientific Statement on
pediatric ABPM [35]. For patients aged ≥ 18 years, ambu-
latory hypertension is defined by adult criteria [36].
Normal ambulatory blood pressure is defined as both
wake and sleep mean ambulatory SBP and DBP less than
the height-sex referenced 95th percentile.
N-of-1 trial design
Establish baseline blood pressure
Baseline BP is defined as the wake mean SBP on the
most recent 24-h ambulatory blood pressure monitoring
(ABPM) off antihypertensive therapy. If it has been over
a year since the last ABPM off therapy, the n-of-1 trial
begins with a washout of previous antihypertensive ther-
apy for at least 2 weeks followed by a repeat ABPM to
confirm the need for ongoing therapy and to establish
the baseline BP.
Treatment cycles
The medications are prescribed in random order at typ-
ical starting weight-based doses (Table 1). The first week
of each 2-week treatment period is considered a washout
period, in which the effects of the previous treatment
are expected to diminish and the effects of the current
treatment commence [37–39]. No assessment of BP re-
duction is taken during the washout period. At the
end of the second week (day 13–14), ABPM is per-
formed for a 24-h period with readings every 30 min
(using SpaceLabs Ultralite 90217 monitors, SpaceLabs,
Inc., Issaquah, WA, USA).
A clinic visit is completed on day 14 of each 2-week
treatment period. At this visit, clinic BP is measured
using standard methodology [10] with an oscillometric
device (Spot Vital Signs LXi, Welch Allyn, Skaneateles
Falls, NY, USA [40]) for four repeated seated measure-
ments. In addition, at each visit the patient is weighed,
interim medical history is obtained, side effects are
assessed using a questionnaire, pill count is performed,
ABPM activity diary is confirmed, and ABPM data is
downloaded.
Cycle 1 is defined as the initial 6 weeks of treatment
periods, during which the three options are assessed for
2 weeks each (Fig. 1). At the clinic visit marking the end
of Cycle 1, the physician, patient, and parents discuss
the comparative effectiveness and tolerability of each of
the tested options. The drug that produces either an
unacceptable side effect or the smallest decrease in
ambulatory wake SBP will be removed from consider-
ation. The remaining two drugs are repeated for 2-week
treatment periods (Cycle 2) in random order to confirm
which drug yields the greatest reduction in BP without
unacceptable side effects. If normal ambulatory blood
pressure is achieved in Cycle 1 with either of the two
drugs to be repeated, the doses are not changed for
Cycle 2. If ambulatory hypertension persists in Cycle 1
on all tested therapies, the doses for the medications are
increased for the subsequent treatment periods accord-
ing to a preplanned protocol (Table 1).
Trial conclusion
The trial is concluded after a drug has been shown to
produce normal ambulatory BP on at least two treat-
ment periods without unacceptable side effects. If more
than one drug meets these criteria, the physician and the
family employ shared decision making to determine the
Table 1 Dose adjustment plan
Initial dose Dosing adjustment Maximum dose
Amlodipine 0.1 mg/kg/dose Qday (max 5 mg/day) Double dose 10 mg/day
Hydrochlorothiazide 1 mg/kg/dose Qday (max 25 mg/day) Double dose 50 mg/day or 3 mg/kg/day
Lisinopril 0.1 mg/kg/dose Qday (max 10 mg/day) Double dose 40 mg/day or 0.6 mg/kg/day
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final preferred therapy, based on greatest average reduc-
tion in wake BP or side effect experience. If the patient
or family chooses to withdraw from the n-of-1 trial
before Cycle 2 can be completed, the data from Cycle 1
is used to determine the preferred drug. If none of the
treatments result in normal ambulatory BP despite max-
imal doses, the trial is concluded and the patient returns
to usual care at the Pediatric Hypertension Clinic to
begin a combination therapy.
Patient measures
Ambulatory BP monitoring
We use ABPM instead of clinic BP measurements to
assess BP reduction on treatment for several reasons.
Multiple measurements are obtained with each 24-h
reading, resulting in reduced variability and greater
reproducibility of measurements compared to office BP
readings [41–45]. This provides greater precision in our
ability to discriminate between the effects of each drug
within a single patient. ABPM allows for blinded collec-
tion of BP measurements. ABPM eliminates the white-
coat effect, which may vary by antihypertensive drug class
[46]. ABPM has been shown to be an important tool
in evaluating the efficacy of BP medications in adults
[47, 48], in discriminating the comparative effectiveness
of different antihypertensive drugs in adults [49, 50], and
has been suggested as a superior measurement tool in
hypertensive children [41, 51].
Side effects
A side effect questionnaire has been developed for this
project to identify unacceptable side effects (Fig. 2). The
Fig. 2 Side effect questionnaire
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questionnaire includes an open-ended prompt to list
all unpleasant effects from the medication, with a rat-
ing scale for how bothersome the effect is and
whether it is considered unacceptable. The question-
naire was piloted in a sample group of adolescent patients
in our clinic. We used the technique of translation with
back-translation to create a Spanish language version of
the questionnaire.
Safety and adverse events
If the patient takes either lisinopril or hydrochlorothia-
zide for the first time during the course of the n-of-1
trial, blood monitoring is performed two weeks after
starting the medication as per usual clinical practice. If
laboratory testing shows abnormal chemistry (excessive
change in serum creatinine or potassium levels), then
that treatment will be removed from consideration as a
preferred drug. BP will be checked in clinic and in the
ambulatory setting every two weeks. If BP on a particular
treatment is considered by the physician to be dangerously
high or low for that patient, the drug will not be repeated.
Demographic data and baseline characteristics
For all participants, at the first visit we collect information
on patient age, gender, weight, height, body-mass index,
race/ethnicity, self-reported exercise activity (number of
hours of exercise in a usual week), and insurance cover-
age. We also collect parental data on age, marital status,
total number of children in the household, race/ethnicity,
employment, and educational attainment.
Adherence to study procedures
We anticipate that the extra effort required to partici-
pate in the n-of-1 trial compared to usual care (frequent
clinic visits and the repeated use of 24-h ABPM) will
deter some families from participation. In order to
maximize adherence, we utilize concepts derived from
motivational interviewing, using an empathetic approach
to help families explore and resolve the potential hin-
drances to compliance with study procedures before
they begin the n-of-1 trial. We also provide external
motivation with financial incentives to the patient, offer-
ing gift cards in gradually increasing amounts (ranging
from $15–$40 per card) for each adequate ABPM read-
ing to motivate the participants to comply with repeated
ABPMs as they progress through the n-of-1 trial. An
adequate ABPM study must contain at least 18 h of
measurements.
We expect that some families might find it difficult
to present to our clinic during regular office hours
for visits every 2 weeks. With that in mind, for all
visits associated with the n-of-1 trial, we offer extended
office hours and validated parking, and we do not charge
patients or insurance companies for the visits or ABPM
interpretation.
Adherence to the prescribed therapy is determined
using a pill count at each visit. Percent adherence is
calculated as ([number of pills taken] ÷ [number of pills
expected to have been taken]) × 100.
Acceptability questionnaire
At the final visit, participants complete a survey to
assess the acceptability of the n-of-1 trial. Questions
are asked on a four-point response scale, addressing
whether the monetary incentives (gift cards and park-
ing validations) influenced their willingness to partici-
pate. Open-ended questions explore the importance of
after-hour options and the most satisfying and most diffi-
cult aspects of the n-of-1 trial.
Power calculation and analytic plan
The aggregate data from all completed n-of-1 trials will
be combined to assess the primary outcome, which is
the percentage of patients for whom each drug is se-
lected as the preferred therapy. For our primary aim of
determining if any drug will be selected for 80 % or
more of the subjects, a frequentist approach will be used
to calculate for each drug a point estimate and 95 %
binomial confidence interval for the proportion of indi-
viduals who prefer that drug. Our primary hypothesis of
treatment equipoise will be confirmed if the upper limit
of the 95 % confidence interval does not reach 80 % for
any of the drugs (that is, the observed proportion of
individuals who prefer any one drug will be less than
80 %).
With the expectation of recruitment of 75 subjects
(2 to 3 per month) and 33 % drop-out rate, we expect to
conduct 50 separate n-of-1 trials over the course of the
funding period. With this number of patients our power
(at an alpha error of 0.05) to reject our hypothesis is
estimated to be ≥ 80 % if in truth any drug is preferred by
60 % or fewer study patients, as this would produce a
95 % confidence interval which does not reach 80 %.
We anticipate that routine use of n-of-1 trials might
be considered for use in clinical practice if there is no
drug that is preferred for ≥ 80 % of patients needing
treatment. If no drug is preferred for a high proportion
of patients, we will also conduct exploratory analyses to
predict which drug is most likely to be preferred for
individual patients based on their baseline characteristics
(race/ethnicity, gender, age, physical activity). These
analyses will be conducted using hierarchical logistic
models including the baseline covariates as predictors
and subject-specific random effects (to account for
within-subject correlation).
We will also employ a Bayesian approach to analysis.
Prior probabilities that any drug will be selected as a
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preferred drug are completely uninformed, given the
lack of previous head-to-head comparisons of antihyper-
tensive drugs in children. Each drug will be assigned a
prior probability of 33 % (with 95 % credible intervals
10–90 %) to be selected as a preferred drug. We will
update the overall probabilities after all n-of-1 trials are
complete, and report point estimate and credible inter-
vals for the primary outcome. We will calculate the
probability that this proportion is > 80 %. Assuming a
prior probability of 33 % and a sample size of 50, if the
true rate of drug A being a preferred drug is 60 %, we
will have ≥ 90 % power to reject our primary hypothesis.
In short, we will have sufficient sample size to deter-
mine if a single drug is preferred by the overwhelming
majority of patients.
Data management
Study data is managed using REDCap (Research Elec-
tronic Data Capture) hosted at UTHealth [52]. REDCap
is a secure, web-based application designed to support
data capture for multiple purposes, including research
and quality improvement.
Ethics approval
The Committee for the Protection of Human Subjects
at the UTHealth McGovern Medical School assessed
the study protocol and determined that formal ap-
proval was not required, as they considered the pro-
posal likely to reduce patient risk and classified this
study as a quality improvement project (HSC-MS-13-
0287). Verbal informed consent is obtained from all
participants. Patients are made aware that their par-
ticipation is voluntary, and they can withdraw at any
time. The question of whether n-of-1 trials should be
considered clinical care, quality improvement, and/or
research has been discussed elsewhere [53]. Trad-
itional distinctions between patient care and quality
improvement initiatives have been seriously ques-
tioned with a growing belief that the important issue
is whether patient risk is increased relative to usual
patient care [54, 55]. Since each therapy tested in the
n-of-1 trials is commonly used in routine clinical
practice for the treatment of hypertension in children,
we do not expect any additional risk to the par-
ticipants relative to usual patient care. This series of
n-of-1 trials is designed to optimize individual patient
care in our center, although we expect some
generalizable insights to result from our data.
Discussion
As more children are prescribed antihypertensive ther-
apy for primary hypertension, the need for comparative
effectiveness data on the therapeutic options has become
more pressing. N-of-1 trials provide physicians with this
data from their own patients, allowing the objective
evaluation of potentially beneficial therapies while min-
imizing bias, reducing the time spent on therapies which
do not work for that patient, and resolving therapeutic
uncertainty much faster than usual care.
Trial status
The study opened to recruitment in June 2013, with
recruitment expected to end in December 2015. The
future reports from this study will follow the CONSORT
extension for reporting n-of-1 trials (CENT) [56].
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